Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more ...